Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Biotech companyLabelled by claude-haiku-5.5 from the firm's FDA names. It is not an FDA field. in FranceLabelled by claude-haiku-5.5 from the firm's FDA names. It is not an FDA field.. FDA records under its name, each linked to the record.
As of Nov 16, 2026, FDA's public records list DBV Technologies S.A. with 1 complete response letter. The most recent is a complete response letter dated Aug 3, 2020: Complete response letter, BL 125713.
Complete response letters: 1
Records by Year
Drug approvals, 510(k) clearances, recalls and letters, 2017 to 2026 to date
How to read this
A hatched bar is a year that is not over, so its count covers only part of the year.
02017Records0
020182018Records0vs 2017+0
02019Records0vs 2018+0
120202020Records1vs 2019+1
02021Records0vs 2020−1
020222022Records0vs 2021+0
02023Records0vs 2022+0
020242024Records0vs 2023+0
02025Records0vs 2024+0
020262026 to dateRecords0
Latest Records
Newest first across sources; each opens the record
11 trials since 2013, 7 ongoing, by the sponsor of the products; see every authorized trial
Viaskin peanut patch (dbv712) expanded access clinical trial in peanut-allergic children previously enrolled in a dbv712 clinical studyJun 26, 2026 · Pending · VIASKIN (DBV712)
A phase 2, open label study to assess ad lib consumption of peanut in peanut allergic infants 6-through 12-months-old with epicutaneous…May 4, 2026 · Ongoing · DBV712 (VIASKIN PEANUT PATCH)
A phase 3, double-blind, placebo-controlled, randomized study to assess the safety of epicutaneous immunotherapy with dbv712 250 ¿g in…Jun 13, 2025 · Ongoing · VIASKIN PEANUT (DBV712)
A phase 3, double-blind, placebo-controlled, randomized study to assess the efficacy and safety of epicutaneous immunotherapy with dbv712…Mar 2, 2023 · Ongoing · VIASKIN PEANUT (DBV712) / PEANUT CHALLENGE MEAL (PCM) / SOLUPRICK POSITIVE AND NEGATIVE CONTROL SOLUTIONS / ALK 762 PEANUT SOLUTION
A phase 2 study to evaluate the sensitivity and specificity of dbv1605, a ready to use atopy patch test for the diagnosis of…Jun 3, 2020 · Ongoing · DBV1605 (MILK ALLERGEN EXTRACT) / HISTAMINE DIHYDROCHLORIDE
A double-blind, placebo-controlled, randomized phase III trial to assess the safety and efficacy of viaskin peanut in peanut-allergic young…Oct 31, 2018 · Ongoing · VIASKIN PEANUT (DBV712)
Open-label follow-up study of the pepites study to evaluate the long-term efficacy and safety of viaskin peanutNov 18, 2016 · Closed · VIASKIN PEANUT / HISTAMINE / ALK 762 PEANUT / PEANUT POWDER
Long-term assessment of safety and therapeutic benefit of viaskin peanut epicutaneous treatment in peanut-allergic children. a 6-month…Sep 7, 2016 · Closed · VIASKIN PEANUT (DBV712) / HISTAMINE / ALK 762 PEANUT
Spellings are joined only when they reduce to the same name, or a reviewed source names the same company. Sharing an FDA establishment number (FEI) is not enough: contract sites make products for many firms. Facts marked AI were labelled by a language model from the firm's FDA names; everything else comes from FDA or Wikidata.How this page is built